Ovid Therapeutics (OVID) Change in Cash (2016 - 2026)

Ovid Therapeutics has reported Change in Cash for 11 years, with the latest figure at $80.9 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Cash rose 1666.52% year-over-year to $80.9 million; the trailing twelve-month figure through Mar 2026 stood at $72.9 million (up 856.83% YoY), and the FY2025 full-year result was -$13.1 million, down 1676.76% from the prior year.
• Change in Cash for Q1 2026 stood at $80.9 million, up from -$7.5 million in the prior quarter.
• The five-year high for Change in Cash was $80.9 million in Q1 2026, with the low at -$93.9 million in Q2 2022.
• Historically, Change in Cash has averaged -$5.5 million across 5 years, with a median of -$7.5 million in 2025.
• Annual changes were most pronounced in 2022 — Change in Cash sank 349.4% — and 2026, when it jumped 1666.52%.
• Ovid Therapeutics' Change in Cash stood at -$13.4 million in 2022, then slumped by 127.01% to -$30.4 million in 2023, then surged by 137.13% to $11.3 million in 2024, then tumbled by 166.09% to -$7.5 million in 2025, then soared by 1184.89% to $80.9 million in 2026.
• The last three Change in Cash figures came in at $80.9 million (Q1 2026), -$7.5 million (Q4 2025), and -$7.8 million (Q3 2025), per Business Quant data.